Dupilumab efficacy in patients with type 2 asthma and early Feno level reductions
Dupilumab sustained efficacy for up to 3 years in patients with and without a minimally important early reduction in Feno level. Greater improvements were seen in patients with an early reduction in Feno level, but patients without such a reduction also showed favorable outcomes during their treatment with dupilumab.
Authors
- Christian Domingo (ORCID: https://orcid.org/0000-0001-8358-773X)
- Juby A. Jacob‐Nara (ORCID: https://orcid.org/0000-0002-5372-8762)
- Rebecca Gall
- William W. Busse (ORCID: https://orcid.org/0000-0003-2591-4696)
- Nami Pandit‐Abid (ORCID: https://orcid.org/0000-0002-1072-2897)
- Ian Pavord (ORCID: https://orcid.org/0000-0002-4288-5973)
- Amr Radwan (ORCID: https://orcid.org/0000-0003-1658-5229)
- Paul J. Rowe
- Changming Xia (ORCID: https://orcid.org/0000-0002-5703-5074)
- Michael E. Wechsler
- Yamo Deniz
Institutions
- University of Wisconsin–Madison (US)
- Regeneron (United States) (US)
- Morristown Medical Center (US)
- National Jewish Health (US)
- National Institute for Health and Care Research (GB)
- Corporació Sanitària Parc Taulí (ES)
- C3I (United States) (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Journal of Allergy and Clinical Immunology Global
- Published
- 2025-04-15
- DOI
- https://doi.org/10.1016/j.jacig.2025.100474
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi
- Regeneron Pharmaceuticals